source
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncologyGilead Sciences announced a licensing agreement with Vir Biotechnology to access Vir's dual-masked PRO-XTEN T-cell engager platform for oncology. Under the deal, Vir will discover, design and opti…
- Roche signs $1 billion deal with China’s Rona Therapeutics for RNAi obesity drugRoche announced a new agreement with Chinese biotech Rona Therapeutics to acquire an experimental RNA interference therapy targeting the protein ALK7 for obesity. Under the terms, Roche will pay $…